Acuitas Lipid 17 (ALC-0315 retro-ester) · DCL0033

Formulation & Performance

Formulation & In Vivo Data

Values shown are literature-reported results for the cited formulation and study conditions. DC Chemicals supplies the lipid only; these results do not guarantee performance in other formulations or experiments. For research use only.

Formulation components and molecular-weight conversion

A · Compound 17 : DSPC : Cholesterol : PEG-DMA = 50 : 10 : 38.5 : 1.5 mol%

Example 3, Table 3, printed pp.50–51 / PDF pp.52–53 · WO2017075531A1 · Patent

Component / DC productMW (g/mol)mol%Calculated mg at 1 µmol total lipid
Acuitas Lipid 17 · DCL0033766.29500.383145
DSPC · DC57005790.15100.079015
Cholesterol · DCD-041386.6538.50.148860
PEG-DMA (C14/C14; PEG2000) · Not assignedNot assigned1.5Not assigned

PEG-DMA: 2-[2-(ω-methoxy(polyethyleneglycol2000)ethoxy]-N,N-ditetradecylacetamide. Whole-conjugate grade-average MW and a verified DC catalog mapping are not assigned. Its mass and complete mass percentages remain unavailable until MW is entered.

Example 3, printed p.50 / PDF p.52; DC57005 / DCD-041 specifications · WO2017075531A1 · Patent

Component mass calculator

Calculated from total lipid amount, molar fractions and MW. Editable values are planning scenarios; the reported table stays unchanged. N/P and RNA dose are not calculated.

Component / DC productMW (g/mol)mol%mgMass %
Acuitas Lipid 17——
DSPC——
Cholesterol——
PEG-DMA (C14/C14; PEG2000)——

Calculated from total lipid amount, molar fractions and MW. Editable values are planning scenarios; the reported table stays unchanged. N/P and RNA dose are not calculated.

Formulation parameters

Example 1 gives general preparation ranges; the exact settings for the Compound 17 batch are not specified. Table 3 explicitly assigns Compound 17 to formulation A.

N/PN/P was not reported for Compound 17 in the examined patent. The total lipid:mRNA mass ratio is not an N/P ratio.
Total lipid:mRNA (w/w)≈10:1–30:1 · Example 1
Lipid stock / organic phaseEthanol; separate stock and combined organic-phase concentrations are not reported.
RNA aqueous inputFLuc mRNA L-6107, 0.2 mg/mL in 10–50 mM citrate buffer, pH 4, before mixing. Capped/polyadenylated; fully substituted with 5-methylcytidine and pseudouridine.
Mixing / processingSyringe-pump in-line mixing; organic:aqueous ≈1:5–1:3 (v/v); total flow >15 mL/min; total lipid:mRNA ≈10:1–30:1 (w/w). Dialysis to PBS, then 0.2 µm filtration. Exact Compound 17 settings, mixing temperature, dialysis duration and post-mixing concentrations are not reported.
Final administration0.3 or 1.0 mg mRNA/kg, tail vein; PBS after dialysis. Final RNA/lipid concentrations and injection volume are not reported.
Storage and useLNP storage and shelf life are not reported. Collected tissue was snap-frozen in liquid nitrogen and held at −80 °C until analysis; these are tissue-sample conditions.
Size / PDI / EE / ζExample 1 general size range: 55–95 nm, in some instances 70–90 nm, by quasi-elastic light scattering (Malvern Zetasizer Nano ZS). No Compound 17-specific size, PDI, encapsulation efficiency or zeta potential is assigned.

Examples 1–3, printed pp.46–50 / PDF pp.48–52 · WO2017075531A1 · Patent

LNP apparent pKa

Example 2, printed p.48 / PDF p.50; Table 3, printed p.51 / PDF p.53 · WO2017075531A1 · Patent

6.28

Measured in formulated LNPs by TNS fluorescence titration; pH at half-maximal fluorescence from a sigmoidal fit. No uncertainty is given for Compound 17.

LNP stock0.4 mM total lipid · PBS
LNP assay24 µM total lipid · 2 mL
Buffer10 mM HEPES + 10 mM MES + 10 mM ammonium acetate + 130 mM NaCl
pH2.5–11
TNS stock100 µM · H₂O
TNS final1 µM
ReadoutRoom temperature · Ex321 / Em445 nm · SLM Aminco Series 2

Example 2; Table 3, Compound 17 · WO2017075531A1 · Patent

Cell performance

No Compound 17-specific cell-transfection or cytotoxicity experiment was reported in the examined patent.

Complete patent; Examples 1–3; Tables 2–3 · WO2017075531A1 · Patent

Animal performance

The source reports ± values, but does not state animal n, SD/SEM or significance tests for Compound 17.

Example 3; Table 3, printed p.51 / PDF p.53 · WO2017075531A1 · Patent

Mouse liver luciferase at 4 h after tail-vein injection; doses are mg mRNA/kg. The row does not identify strain/sex/age. Example 1 lists 6–8-week female C57BL/6 mice and 8–10-week CD-1 mice without assigning Compound 17 to either group.

0.3 mg mRNA/kg body weight

275 ± 139 ng luciferase/g liver · 4 h · IV

Example 3, Table 3, printed p.51 (PDF p.53) · WO2017075531A1 · Patent

1 mg mRNA/kg body weight

1554 ± 761 ng luciferase/g liver · 4 h · IV

Example 3, Table 3, printed p.51 (PDF p.53) · WO2017075531A1 · Patent

Other lipid rows appear in Tables 2–3; no matched-control statistical analysis is supplied for Compound 17. Table 2 comparator formulations use PEG-DMG, while Compound 17 formulation A uses PEG-DMA.

No Compound 17-specific toxicity, clinical chemistry, histology or safety study is reported in the examined patent.

Values shown are literature-reported results for the cited formulation and study conditions. DC Chemicals supplies the lipid only; these results do not guarantee performance in other formulations or experiments. For research use only.

Original literature performance evidence

Table 3, printed p.51 / PDF p.53 · WO2017075531A1 · Patent

Original Table 3, printed p.51 / PDF p.53. Read the row labeled 17: formulation A; pKa 6.28; liver luciferase 275±139 and 1554±761 ng/g at 0.3 and 1.0 mg mRNA/kg, respectively, 4 h after IV injection. Sample size and the definition of ± are not stated.
Original Table 3, printed p.51 / PDF p.53. Read the row labeled 17: formulation A; pKa 6.28; liver luciferase 275±139 and 1554±761 ng/g at 0.3 and 1.0 mg mRNA/kg, respectively, 4 h after IV injection. Sample size and the definition of ± are not stated.
Open full-size original

WO2017075531A1, Table 3, printed p.51 · WO2017075531A1 · Patent

Cell experiment protocol

No Compound 17-specific cell-transfection or cytotoxicity experiment was reported in the examined patent.

Complete patent; Examples 1–3; Tables 2–3 · WO2017075531A1 · Patent

Animal experiment protocol

Example 1 gives general preparation ranges; the exact settings for the Compound 17 batch are not specified. Table 3 explicitly assigns Compound 17 to formulation A.

Table 3, printed p.51 (PDF p.53); Examples 1–3, printed pp.46–50 (PDF pp.48–52) · WO2017075531A1 · Patent

  1. Dissolve Compound 17, DSPC, cholesterol and PEG-DMA in ethanol at 50:10:38.5:1.5 mol%.
  2. Prepare the aqueous mRNA input as described below.
  3. Apply the published general mixing and processing ranges below; exact Compound 17 settings are not stated.
  4. Administer 0.3 or 1.0 mg mRNA/kg via the tail vein and collect liver at 4 h; retain the model limitations stated above.
  5. Weigh collected tissues, snap-freeze in liquid nitrogen and store at −80 °C until analysis.
  6. Homogenize ≈50 mg liver in a 2 mL FastPrep tube with a ¼-inch ceramic sphere and 500 µL room-temperature Glo Lysis Buffer: FastPrep24, 2 × 15 s at 6.0 m/s. Incubate 5 min at room temperature; dilute 1:4 in Glo Lysis Buffer.
  7. Mix 50 µL diluted homogenate with 50 µL SteadyGlo substrate; shake 10 s, incubate 5 min and read using CentroXS3 LB960. Normalize RLU to protein determined by BCA; use a QuantiLum recombinant-luciferase standard curve. Table 3 reports ng luciferase/g liver.

Lipid stock / organic phase

Ethanol; separate stock and combined organic-phase concentrations are not reported.

Ethanol; separate stock and combined organic-phase concentrations are not reported.

RNA aqueous input

FLuc mRNA L-6107, 0.2 mg/mL in 10–50 mM citrate buffer, pH 4, before mixing. Capped/polyadenylated; fully substituted with 5-methylcytidine and pseudouridine.

FLuc mRNA L-6107, 0.2 mg/mL in 10–50 mM citrate buffer, pH 4, before mixing. Capped/polyadenylated; fully substituted with 5-methylcytidine and pseudouridine.

Mixing / processing

Syringe-pump in-line mixing; organic:aqueous ≈1:5–1:3 (v/v); total flow >15 mL/min; total lipid:mRNA ≈10:1–30:1 (w/w). Dialysis to PBS, then 0.2 µm filtration. Exact Compound 17 settings, mixing temperature, dialysis duration and post-mixing concentrations are not reported.

Syringe-pump in-line mixing; organic:aqueous ≈1:5–1:3 (v/v); total flow >15 mL/min; total lipid:mRNA ≈10:1–30:1 (w/w). Dialysis to PBS, then 0.2 µm filtration. Exact Compound 17 settings, mixing temperature, dialysis duration and post-mixing concentrations are not reported.

Final administration

0.3 or 1.0 mg mRNA/kg, tail vein; PBS after dialysis. Final RNA/lipid concentrations and injection volume are not reported.

0.3 or 1.0 mg mRNA/kg, tail vein; PBS after dialysis. Final RNA/lipid concentrations and injection volume are not reported.

Storage and use

LNP storage and shelf life are not reported. Collected tissue was snap-frozen in liquid nitrogen and held at −80 °C until analysis; these are tissue-sample conditions.

LNP storage and shelf life are not reported. Collected tissue was snap-frozen in liquid nitrogen and held at −80 °C until analysis; these are tissue-sample conditions.

Table 3, printed p.51 (PDF p.53); Examples 1–3, printed pp.46–50 (PDF pp.48–52) · WO2017075531A1 · Patent

References

Ansell SM, Du X. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids. WO2017075531A1. Acuitas Therapeutics Inc. Published 4 May 2017. · WO2017075531A1 · Patent